BNC-105 is under clinical development by Bionomics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BNC-105’s likelihood of approval (LoA) and phase transition for Metastatic Colorectal Cancer took place on 27 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BNC-105 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BNC-105 is under development for the treatment of metastatic colorectal cancer, acute myeloid leukemia (AML), and relapse and refractory chronic lymphocytic leukaemia. The drug candidate is administered through the intravenous route. BNC-105P is a disodium phosphate ester (phosphorylated) prodrug form of BNC-105. It is a benzofuran-based vascular disrupting agent (VDA) derivative. BNC-105 is a tubulin polymerization inhibitor. The drug candidate is based on MultiCore technology.
It was also under development for brain cancer, colon cancer, head and neck cancer, lung cancer and prostate cancer, epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer, colorectal cancer, breast cancer, soft tissue sarcoma, solid tumor, ovarian cancer, malignant pleural mesothelioma, metastatic clear cell renal cell carcinoma, advanced melanoma.
Bionomics, is a biopharmaceutical company that discovers and develops treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer’s disease. The company provides pipeline products such as BNC210, BNC 105, BNC101 and BNC375, among others. It uses various technology platforms including multicore; ionX; and CSC Rx Discovery platform for discovering highly active, functional therapeutic antibodies and small molecule candidates that target cancer stem cells, among others. Bionomics‘ ionX includes systems for high throughput electrophysiology for early and high content evaluation of drug hits. The company conducts clinical studies including post-traumatic stress disorder study, multiple ascending dose study, and generalized anxiety disorder study, dose esclaltion study. Bionomics is headquartered in Thebarton, South Australia, Australia.
Quick View BNC-105 LOA Data
|Highest Development Stage|